Navigation Links
PAREXEL Expands Global Clinical Pharmacology Capabilities
Date:3/31/2008

BOSTON, March 31 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company had completed the expansion of three Clinical Pharmacology Research Units located in Baltimore, Maryland in the United States; London, United Kingdom; and Berlin, Germany in order to meet growing client demand for expertise-based studies in the early phases of clinical development.

"Continued expansion of local capabilities combined with an integrated global clinical pharmacology presence has been a cornerstone of PAREXEL's leadership in early clinical development. As biopharmaceutical companies have been conducting more Phase I and Proof of Concept studies with increasing complexity, PAREXEL has been well positioned to meet their needs. In this regard, we are a top provider of expertise-based Phase I services and have more than 550 beds, which is among the largest capacities worldwide," said Herman Scholtz, M.D., Head of International Clinical Pharmacology, PAREXEL. "Clients rely on our in-depth medical and therapeutic expertise to help them conduct rigorous clinical trials in order to identify and select promising new compounds." Dr. Scholtz added, "Long before hospital-based units became an industry best practice, PAREXEL saw the benefit of that approach and located our clinical pharmacology research units in hospitals in order to provide a safe, high-quality environment for early phase development activities."

In Baltimore, PAREXEL's Clinical Pharmacology Research Unit has been expanding capabilities and capacity for client programs since 2001, when the unit opened. With its most recent expansion, the unit now has 90 beds, representing the larg
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
8. Gates Foundation Seeks Proposals for Innovative Global Health Research
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
... EVANSTON, Ill., Dec. 16 Naurex Inc., a new clinical ... disorders based on its novel GFPA NMDA receptor modulators, today ... of its lead compound GLYX-13 and has successfully dosed the ... functional partial agonist (GFPA) selective modulator of the NMDA receptor, ...
Cached Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
(Date:7/30/2014)... 2014 Ticket Down is a ... vs. Chivas Guadalajara friendly exhibition match at the Red ... the one team that was left standing as the best ... through the world’s largest football competition and even embarrassed the ... to the cup. Germany was led by seven players that ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... in sub-Saharan Africa is being revitalized and expanded ... enrollment, broadening curricula, upgrading Internet access and providing ... In the first substantial publication by participants of ... more than 225 authors detailed progress being made ... a supplement being published today by the journal ...
(Date:7/30/2014)... artemisinin, the main drug to treat malaria, is ... Plasmodium falciparum ( P. falciparum ) parasites ... by a genetic mutation in the parasites. However, ... to a standard three-day coursehas proved highly effective ... published today in the New England Journal ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Relocates to New Facility 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2
... -- Teenage girls who develop post-traumatic stress disorder after being ... research shows. In the study, researchers analyzed data collected ... part in a national telephone survey and were interviewed up ... time, 270 of the girls (15 percent) reported sexual victimization. ...
... Chicago College of Medicine have been awarded more than $11.7 ... The study, part of a multi-pronged investigation into acute ... Lung and Blood Institute, one of the National Institutes of ... acute respiratory distress syndrome, result from pulmonary edema -- leaky ...
... , FRIDAY, July 29 (HealthDay News) -- An ... -- a specific breed of dog known for truffle hunting, ... newly identified gene has enabled the development of a DNA ... for humans, providing new perspective on the development of a ...
... is available in Spanish . Patients suffering ... attacked and pursued, with the particularity that they express them ... Neurology has published the third consecutive work in five ... The first work showed in 2006 that 45% ...
... ethnic groups are more likely than others to store dangerous fat ... new study. This organ-hugging fat, which can lead to ... South Asia, the Canadian researchers reported in the July 28 online ... study showed South Asians have less space to store fat below ...
... bikers, brains, may also be contributing to hearing loss. ... out why. The distinctive roar of a Harley,s ... source of noise for motorcyclists is actually generated by ... speeds, the sound can exceed safe levels. Now, scientists ...
Cached Medicine News:Health News:Sexual Assault Doesn't Cause Binge Drinking in Girls: Study 2Health News:$12 million NIH grant to study acute lung injury 2Health News:New Dog Gene May Shed Light on Childhood Epilepsy 2Health News:REM sleep behavior disorder is a risk factor for Parkinson's disease 2Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2
... K-ASSAY ASO / RF / ... to be used as a ... concentration for monitoring the performance ... Rheumatoid Factor (RF), and C-Reactive ...
... of benchtop microcentrifuges with the 5424. ... aerosol-tight rotor and a unique, contoured ... ,Model 5424 expands its application range ... microcentrifuge tubes, miniprep spin columns and ...
... hand, the Jarvik 2000 pump is about the ... titanium shell sits a direct-current motor, a rotor ... moving part: a small, spinning titanium impeller that ... 7 liters per minute. Rather than take over ...
... VentrAssist is a new third generation cardiac assist ... heart transplants for patients suffering heart failure., ,It ... left ventricle of the diseased heart to help ... restoring a better quality of life. , ,It ...
Medicine Products: